摘要
背景:最近的研究表明,内分泌激素和以内分泌为基础的治疗可能会影响脂蛋白的代谢,尽管相关的机制尚未明确。奥巴目的:总结与血清脂蛋白特征相关的内分泌机制的现有数据,并讨论这些关系的临床意义。 方法:采用“增量”、“GLP-1”、“GIP”和“脂类”、“血脂异常”、“甘油三酯”、“载脂蛋白B48”等术语对PubMed进行检索。所有文章均以英文发表,至六月止。对2016年进行评估,并在此提供相关信息。 结果:GLP-1和提高其活性的疗法对脂蛋白代谢有利作用,其作用机制是降低三糖的空腹和餐后浓度。杀灭剂和少量提高HDLs的浓度和功能。此外,GLP-1受体激动剂的使用通常会导致更大、更少动脉粥样硬化的颗粒。造成这些变化的机制包括glp-1对富含甘油三酯的脂蛋白的肝和肠道产生的直接影响,即glp-1诱导产生a的增加。胰岛素的ND功能,激活中枢神经系统的特定区域,以及增加外周甘油三酯的利用以产生能量。另一方面,GLP-2增加了饮食脂肪的吸收和富含甘油三酯的脂蛋白的产生,而GIP对脂质代谢的作用仍然是不确定的。 结论:GLP-1和增量疗法对脂质代谢有较好的影响.这些作用可能有助于以内分泌为基础的治疗动脉粥样硬化和脂肪肝的有益作用。疾病.
关键词: 内分泌,GLP-1,GLP-2,GIP,甘油三酯,高密度脂蛋白,血脂异常。
Current Medicinal Chemistry
Title:Incretins and Lipid Metabolism
Volume: 25 Issue: 18
关键词: 内分泌,GLP-1,GLP-2,GIP,甘油三酯,高密度脂蛋白,血脂异常。
摘要: Background: Recent findings indicate that incretin hormones and incretin-based therapies may affect the metabolism of lipoproteins, although the corresponding mechanisms are not clearly defined.
Objective: To summarize the available data on the mechanisms linking incretins with the characteristics of serum lipoproteins and discuss the clinical implications of these relationships.
Methods: PubMed was searched using the terms “incretins”, “GLP-1”, “GIP” and “lipids”, “dyslipidemia”, “triglycerides”, “apolipoprotein B48”. All articles published in the English language until June 2016 were assessed and the relevant information is presented here.
Results: GLP-1, and therapies that increase its activity, exert a beneficial effect on lipoprotein metabolism that is translated in a reduction in the fasting and postprandial concentration of triglycerides and a small improvement in the concentration and function of HDLs. In addition, a shift towards larger, less atherogenic particles usually follows the administration of GLP-1 receptor agonists. The mechanisms that underlie these changes involve a direct effect of GLP- 1 on the hepatic and intestinal production of triglyceride-rich lipoproteins, the GLP-1 induced increase in the production and function of insulin, the activation of specific areas of central nervous system as well as the increase in the peripheral utilization of triglycerides for energy production. On the other hand, GLP-2 increases the absorption of dietary fat and the production of triglyceride-rich lipoproteins while the role of GIP on lipid metabolism remains indeterminate.
Conclusion: GLP-1 and incretin-based therapies favorably affect lipid metabolism. These effects may contribute to the beneficial effects of incretin-based therapies on atherosclerosis and fatty liver disease.
Export Options
About this article
Cite this article as:
Incretins and Lipid Metabolism, Current Medicinal Chemistry 2018; 25 (18) . https://dx.doi.org/10.2174/0929867324666170414164244
DOI https://dx.doi.org/10.2174/0929867324666170414164244 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Five Markers Capable to Identify Passive Smoking Exposure Associated with Endothelial Dysfunction in Healthy Individuals
Current Hypertension Reviews Primary and Secondary Insomnia: Prevalence, Causes and Current Therapeutics
Current Medicinal Chemistry - Central Nervous System Agents Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design Neuroimmune Aspects of Sjogren`s Syndrome: Role of VIP/VPAC System in Immune and Salivary Gland Epithelial Cell Function
Current Pharmaceutical Design Membrane Bound Members of the M1 Family: More Than Aminopeptidases
Protein & Peptide Letters <i>Uncaria rhynchophylla</i> and its Major Constituents on Central Nervous System: A Review on Their Pharmacological Actions
Current Vascular Pharmacology Regional Cerebral Blood Flow and Cerebrovascular Reactivity in Alzheimer’s Disease and Vascular Dementia Assessed by Arterial Spinlabeling Magnetic Resonance Imaging
Current Neurovascular Research Early Functional and Structural Microvascular Changes in Hypertension Related to Aging
Current Hypertension Reviews Antisynthetase Syndrome: A Review of Etiopathogenesis, Diagnosis and Management
Current Medicinal Chemistry Novel Therapeutic Agents for Hyperuricemia in Patients with Gout
Current Drug Therapy Statins in Aortic Disease
Current Pharmaceutical Design Conference Report: 7th Clinical Trials on Alzheimer’s Disease Annual Conference, Philadelphia, PA, USA Nov 20-22, 2014
CNS & Neurological Disorders - Drug Targets Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1), a Relevant Target for Diabetic Vasculopathy?
Cardiovascular & Hematological Disorders-Drug Targets Adynamic Ileus Induced by Varenicline
Current Drug Safety Endothelial Dysfunction: The Link Between Homocysteine and Hydrogen Sulfide
Current Medicinal Chemistry Why is the Inhibition of the Renin-Angiotensin System Effective for Preventing Cardiac Events in Patients with Coronary Risk Factors or Coronary Artery Disease?
Current Cardiology Reviews Foreword:
Current Pharmaceutical Design Use of Clinically Available PPAR Agonists for Heart Failure; Do the Risks Outweigh the Potential Benefits?
Current Molecular Pharmacology Spontaneous Chest Abscess Caused by Salmonella Enterica subsp. Arizonae in the Desert Southwest; A Case Report and Review of the Current Literature
Infectious Disorders - Drug Targets Therapeutic Implications of Immune-endocrine Interactions in the Critically Ill Patients
Current Drug Targets - Immune, Endocrine & Metabolic Disorders